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Supplementary Table 1: recruitment by region and GP practice 
 
 Naproxen Colchicine 
   
Recruitment by region, n (%)   
 Keele 55 (27.5%) 52 (26.1%) 
 Southampton 88 (44.0%) 101 (50.8%) 
 Oxford 41 (20.5%) 31 (15.6%) 
 Nottingham 16 (8.0%) 15 (7.5%) 
   
Participants recruited per 
practice, median (IQR)* 
 
2 (1-4) 2 (1-3) 
*75/100 GP practices who agreed to take part recruited at least one participant. 
Numbers recruited per practice ranged from 1 (21 practices) to 41 for the best 
recruiting practice (skewed upwards); overall median of 3 (IQR 1-7). 
IQR, interquartile range 
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Supplementary table 2: per protocol analyses 
 1 2 3 
 Mean 
difference 
(95% CI) 
P 
value 
Mean 
difference 
(95% CI) 
P value Mean 
difference 
(95% CI) 
P 
value 
Day 1 0.01 
(-0.45 to 0.46) 
0.97 -0.04 
(-0.50 to 0.41) 
0.85 -0.04 
(-0.54 to 0.46) 
0.88 
Day 2 -0.43  
(-0.88 to 0.02) 
0.063 -0.47  
(-0.92 to -0.02) 
0.040 -0.57  
(-1.07 to -0.07) 
0.024 
Day 3 -0.11 
(-0.56 to 0.33) 
0.62 -0.17 
(-0.62 to 0.28) 
0.47 -0.20 
(-0.69 to 0.30) 
0.44 
Day 4 -0.11 
(-0.56 to 0.34)  
0.62 -0.19 
(-0.64 to 0.26)  
0.41 -0.23 
(-0.72 to 0.27)  
0.37 
Day 5 -0.16 
(-0.61 to 0.28) 
0.47 -0.25 
(-0.71 to 0.20) 
0.27 -0.23 
(-0.73 to 0.27) 
0.36 
Day 6 -0.18  
(-0.63 to 0.26) 
0.42 -0.31  
(-0.77 to 0.14) 
0.17 -0.22  
(-0.72 to 0.27) 
0.38 
Day 7# 
 
-0.28  
(-0.72 to 0.16) 
0.22 -0.43  
(-0.88 to 0.02) 
0.061 -0.41  
(-0.91 to 0.08) 
0.10 
Overall 
(Days 1-7) 
-0.18  
(-0.54 to 0.17) 
0.32 -0.27  
(-0.62 to 0.09) 
0.14 -0.27  
(-0.67 to 0.13) 
0.18 
Week 4 -0.24 
(-0.68 to 0.20) 
0.29 -0.48 
(-0.94 to -0.03) 
0.038 -0.57 
(-1.07 to -0.07) 
0.025 
       
Definition of per-protocol analyses:- 
1 = No treatment violation by medical record note reporting (no treatment crossover + no 
early cessation of treatment) {n (A/B) = 184/182; 1014 / 1054 repeat data across days 1-7} 
2 = At least 1-day use of randomised treatment by self-report (in addition to 1 above) {n 
(A/B) = 149/155; 998 / 1032 repeat data across days 1-7} 
3 = 7 days (4-7 days) use of randomised treatment naproxen (colchicine) by self-report (in 
addition to 1 above) {n (A/B) = 118/134; 807 / 890 repeat data across days 1-7} 
# Summary is inclusive of minimum data collection (for scores at day 7) 
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Supplementary table 3: Comparison of complete pain resolution over days 1-7 and at 4 
weeks 
  Naproxen Colchicine 2 P value 
      
Day 1  2/160 (1.3%) 8/164 (4.9%) 3.6 0.10* 
Day 2  11/161 (6.8%) 12/164 (7.3%) 0.03 0.87 
Day 3  29/163 (17.8%) 29/166 (17.5%) 0.01 0.94 
Day 4  56/158 (35.4%) 55/168 (32.7%) 0.27 0.61 
Day 5  79/156 (50.6%) 72/159 (45.3%) 0.91 0.34 
Day 6  95/157 (60.5%) 89/160 (55.6%) 0.78 0.38 
Day 7  115/171 (67.3%) 116/173 (67.1%) <0.01 0.97 
Week 4  130/173 (75.1%) 130/177 (73.4%) 0.13 0.72 
      
* Complete-case responders to all pain questions (diary days 1 through 7 and at 4 weeks). 
Median = Day 5 for Naproxen; Median = Day 6 for Colchicine. 
Interquartile range: Day 4, Week 4 [in both treatment groups]. 
P value by Mann-Whitney U test = 0.73.
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Supplementary Table 4: Self-reported daily side-effects within the first week of follow-up – complete-case data 
 Day1 Day2 Day3 Day4 Day5 Day6 Day7 
 N 
(n=160) 
C 
(n=164) 
N 
(n=161) 
C 
(n=164) 
N 
(n=163) 
C 
(n=166) 
N 
(n=160) 
C 
(n=168) 
N 
(n=160) 
C 
(n=162) 
N 
(n=158) 
C 
(n=162) 
N 
(n=172)* 
C 
(n=176)* 
 NP CC NP CC NP CC NP CC NP CC NP CC NP CC 
Nausea 17 
(10.6%) 
15 
(9.1%) 
11 
(6.8%) 
16 
(9.8%) 
7 
(4.3%) 
17 
(10.2%) 
6 
(3.8%) 
11 
(6.5%) 
6 
(3.8%) 
6 
(3.7%) 
2 
(1.3%) 
6 
(3.7%) 
3  
(1.7%) 
5  
(2.8%) 
Vomiting 3 
(1.9%) 
1 
(0.6%) 
2 
(1.2%) 
1 
(0.6%) 
1 
(0.6%) 
1 
(0.6%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
1 
(0.6%) 
0  
(0.0%) 
0  
(0.0%) 
Nausea and/or 
vomiting 
19 
(11.9%) 
16 
(9.8%) 
12 
(7.5%) 
17 
(10.4%) 
7 
(4.3%) 
18 
(10.8%) 
6 
(3.8%) 
11 
(6.5%) 
6 
(3.8%) 
6 
(3.7%) 
2 
(1.3%) 
7 
(4.3%) 
3  
(1.7%) 
5  
(2.8%) 
Dyspepsia 10 
(6.3%) 
13 
(7.9%) 
11 
(6.8%) 
11 
(6.7%) 
11 
(6.7%) 
14 
(8.4%) 
9 
(5.6%) 
11 
(6.5%) 
5 
(3.1%) 
7 
(4.3%) 
6 
(3.8%) 
6 
(3.7%) 
4  
(2.3%) 
6  
(3.4%) 
Abdominal pain 5 
(3.1%) 
7 
(4.3%) 
6 
(3.7%) 
8 
(4.9%) 
7 
(4.3%) 
8 
(4.8%) 
7 
(4.4%) 
8 
(4.8%) 
3 
(1.9%) 
9 
(5.6%) 
2 
(1.3%) 
6 
(3.7%) 
4  
(2.3%) 
6  
(3.4%) 
Headache 9 
(5.6%) 
16 
(9.8%) 
10 
(6.2%) 
12 
(7.3%) 
3 
(1.8%) 
13 
(7.8%) 
3 
(1.9%) 
13 
(7.7%) 
5 
(3.1%) 
10 
(6.2%) 
4 
(2.5%) 
5 
(3.1%) 
3  
(1.7%) 
4  
(2.3%) 
Constipation 8 
(5.0%) 
1 
(0.6%) 
15 
(9.3%) 
2 
(1.2%) 
16 
(9.8%) 
5 
(3.0%) 
8 
(5.0%) 
4 
(2.4%) 
6 
(3.8%) 
3 
(1.9%) 
6 
(3.8%) 
2 
(1.2%) 
5  
(2.9%) 
3  
(1.7%) 
Diarrhoea 7 
(4.4%) 
20 
(12.2%) 
7 
(4.3%) 
28 
(17.1%) 
12 
(7.4%) 
40 
(24.1%) 
10 
(6.3%) 
52 
(31.0%) 
3 
(1.9%) 
34 
(21.0%) 
7 
(4.4%) 
18 
(11.1%) 
5  
(2.9%) 
13 
(7.4%) 
Skin rash 2 
(1.3%) 
3 
(1.8%) 
2 
(1.2%) 
2 
(1.2%) 
0 
(0.0%) 
1 
(0.6%) 
0 
(0.0%) 
1 
(0.6%) 
1 
(0.6%) 
1 
(0.6%) 
0 
(0.0%) 
1 
(0.6%) 
0 
(0.0%) 
2 
(1.1%) 
Any side 
effect(s)# 
54 
(33.8%) 
54 
(32.9%) 
50 
(31.1%) 
64 
(39.0%) 
52 
(31.9%) 
76 
(45.8%) 
45 
(28.1%) 
78 
(46.4%) 
38 
(23.8%) 
52 
(32.1%) 
35 
(22.2%) 
36 
(22.2%) 
26 
(15.1%) 
32 
(18.2%) 
N = Naproxen; C = Colchicine 
* These are higher denominator numbers since questions on side-effects on day 7 were included in minimal data collection retrieval. 
#
 Includes the side-effects listed and ‘other’ (nominated free-text) side-effects.
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Supplementary table 5: Mean (SD) resource use, costs and outcomes per participant 
over 4 weeks follow-up 
 Naproxen (n=200) Colchicine (n=199) Difference (CI) 
RESOURCE USE 
GP visits  0.19 (0.34) 0.27 (0.40) -0.08 (-0.15 to 0.0002) 
Nurse visits 0.05 (0.19) 0.07 (0.22) -0.02 (-0.06 to 0.03) 
Emergency GP visits 0.05 (0.17) 0.04 (0.18) 0.01 (-0.03 to 0.04)  
A and E visits 0.006 (0.07) 0.007 (0.07) -0.001 (-0.02 to 0.01) 
 
COSTS (£) 
Drug costs 0.83 (2.00) 1.20 (2.22) -0.37 (-0.78 to 0.02) 
GP costs 6.44 (11.16) 8.80 (13.16) -2.36 (-4.74 to 0.12) 
Nurse costs 0.66 (2.26) 0.86 (2.71) -0.20 (-0.68 to 0.31) 
Emergency GP costs 2.45 (8.54) 2.14 (8.68) 0.31 (-1.28 to 2.04) 
A and E costs 0.41 (5.10) 0.48 (5.15) -0.07 (-1.21 to 0.95) 
Intervention cost 6.77 (4.56) 9.83 (6.32) -3.06 (-4.17 to -2.08) 
Total cost 17.57 (20.38) 23.31 (23.46) -5.74 (-10.03 to -1.64) 
 
HEALTH OUTCOMES 
Baseline EQ-5D 0.665 (0.21) 0.663 (0.22) 0.002 (-0.04 to 0.04) 
Day 7 EQ-5D 0.882 (0.13) 0.873 (0.14) 0.009 (-0.02 to 0.03) 
Week 4 EQ-5D 0.900 (0.11) 0.894 (0.15) 0.006 (-0.02 to 0.03) 
QALYs 0.0663 (0.008) 0.0657 (0.01) 0.0006 (-0.001 to 0.002) 
Adjusted QALYs+ 0.0662 0.0658 0.0004 
 
WORK-RELATED OUTCOMES 
Time off work (days) 0.40 (2.47) 0.35 (2.51) 0.05 (-0.42 to 0.53) 
Productivity cost (£) 32.16 (190.40) 28.44(207.42) 3.72 (-34.27 to 40.73) 
       
+Adjusted for baseline EQ-5D 
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